Creo Medical Group Plc · LSE:CREO
Creo Medical — Shareholder Meeting (June 2022)
9 slides from Creo Medical's shareholder meeting presentation, Jun 28, 2022
Slide 1: Bringing Advanced Energy to Endoscopy
BRINGING ADVANCED ENERGY TO ENDOSCOPY 2022 Annual General Meeting 28th June 2022
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE This presentation comprises the written materials/slides (“presentation”) concerning Creo Medical Group PLC (the “Company”) and technologies and/or products developed or under development by the Company. By reviewing this presentation you agree to be bound by the followin
Slide 3: Creo Medical Overview
Creo Medical Overview • Creo Medical is an Advanced Energy company principally focussed on treating cancers • Bowel / Upper GI 2016 IPO • First successful human Pancreas procedure Speedboat and CROMA CE Mark and completed plus additional sites and cases in EMEA (~20 2017 FDA clearance, Electroporati
Slide 4: Global Reach, Global Markets (March 2022)
Global Reach, Global Markets (March 2022) 150 R&D/Ops 20 USA 4,800 + 9 Direct UK (x5) USA 26 26 signed 300 90 S&M 270 EMEA Countries Ger, Fra, Spain Hong Kong Countries 10 + in negotiation Hospital, Doctor & People Clinic Customers Indirect 60 G&A 10 APAC 12 Offices Bel/Lux Singapore EMEA & APAC foc
Slide 5: Commercial Highlights
Commercial Highlights Continued growth: • Over 1,000 Speedboat Inject procedures performed to date • Speedboat Inject procedure volumes doubled over previous year • Pipeline of clinicians to be trained under Clinical Education Programme has doubled • 25% increase in the Group’s direct sales force si
Slide 6: Creo – A Global Company
Creo – A Global Company Follow us on Twitter & LinkedIn @CreoEndoscopy and @CreoMedical Around the World in 80 days 6 Strictly Confidential © Creo Medical 2022.
Slide 7: Pathway to success
Pathway to success Retired maths teacher Chris Grayling, 67, from Hamstreet near Ashford, only visited his GP at his wife’s insistence – and tests revealed an 11cm pre-cancerous growth in his bowel. Thanks to Creo's Speedboat Inject device and the excellent staff at East Kent Hospitals University NH
Slide 8: Executing Our Strategy
Executing Our Strategy We have the opportunity to develop the business in multiple ways and at pace through a three-tiered strategy: Build Buy Partner We intend to further develop Creo’s Kamaptive Technology to Acquiring businesses that enhance our Realising the significant potential to license Kama
Slide 9: Anything is possible with the right approach
KW ce... Anything is possible with the right approach